ES2178000T3 - Composiciones y metodos para tratar infecciones usando analogos de indolicidina. - Google Patents
Composiciones y metodos para tratar infecciones usando analogos de indolicidina.Info
- Publication number
- ES2178000T3 ES2178000T3 ES97941352T ES97941352T ES2178000T3 ES 2178000 T3 ES2178000 T3 ES 2178000T3 ES 97941352 T ES97941352 T ES 97941352T ES 97941352 T ES97941352 T ES 97941352T ES 2178000 T3 ES2178000 T3 ES 2178000T3
- Authority
- ES
- Spain
- Prior art keywords
- compositions
- methods
- indolicidine
- analogs
- treat infections
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 208000015181 infectious disease Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- USSYUMHVHQSYNA-SLDJZXPVSA-N indolicidin Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)CC1=CNC2=CC=CC=C12 USSYUMHVHQSYNA-SLDJZXPVSA-N 0.000 abstract 1
- 108091005601 modified peptides Proteins 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
SE PRESENTAN COMPOSICIONES Y PROCEDIMIENTOS PARA EL TRATAMIENTO DE INFECCIONES, ESPECIALMENTE INFECCIONES BACTERIANAS. SE PREPARAN ANALOGOS PEPTIDOS DE INDOLICIDINA QUE CONTIENEN AL MENOS DOS AMINOACIDOS BASICOS. LOS ANALOGOS SE ADMINISTRAN COMO PEPTIDOS MODIFICADOS, QUE CONTIENE PREFERIBLEMENTE UN SOLUBILIZADOR FOTO-OXIDADO.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2475496P | 1996-08-21 | 1996-08-21 | |
| US3494997P | 1997-01-13 | 1997-01-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2178000T3 true ES2178000T3 (es) | 2002-12-16 |
Family
ID=26698836
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES01119148T Expired - Lifetime ES2315252T3 (es) | 1996-08-21 | 1997-08-21 | Composiciones y metodos para tratar infecciones usando analogos de indolicidina. |
| ES97941352T Expired - Lifetime ES2178000T3 (es) | 1996-08-21 | 1997-08-21 | Composiciones y metodos para tratar infecciones usando analogos de indolicidina. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES01119148T Expired - Lifetime ES2315252T3 (es) | 1996-08-21 | 1997-08-21 | Composiciones y metodos para tratar infecciones usando analogos de indolicidina. |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US6180604B1 (es) |
| EP (1) | EP0925308B1 (es) |
| JP (2) | JP2001500477A (es) |
| AT (2) | ATE410441T1 (es) |
| CA (1) | CA2263799A1 (es) |
| DE (2) | DE69739035D1 (es) |
| ES (2) | ES2315252T3 (es) |
| HK (1) | HK1043475B (es) |
| WO (1) | WO1998007745A2 (es) |
Families Citing this family (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE20000918A1 (en) * | 1990-03-22 | 2001-05-30 | Sloan Kettering Inst Cancer | GP75 As a Tumor Vaccine for Melanoma |
| US6180604B1 (en) | 1996-08-21 | 2001-01-30 | Micrologix Biotech Inc. | Compositions and methods for treating infections using analogues of indolicidin |
| US6503881B2 (en) * | 1996-08-21 | 2003-01-07 | Micrologix Biotech Inc. | Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics |
| WO1999043357A1 (en) * | 1998-02-25 | 1999-09-02 | Micrologix Biotech Inc. | Indolicidin and cationic peptides conjugated with polymers |
| US6303575B1 (en) * | 1998-05-12 | 2001-10-16 | The Regents Of The University Of California | Indolicidin analogs and methods of using same |
| WO1999065506A2 (en) * | 1998-06-12 | 1999-12-23 | Micrologix Biotech Inc. | Cancer therapy with indolicidin or cationic peptides and their polymer conjugates |
| US6444645B1 (en) * | 1998-06-18 | 2002-09-03 | The Regents Of The University Of California | Crosslink-stabilized indolicidin analogs |
| US6288212B1 (en) * | 1998-08-28 | 2001-09-11 | The University Of British Columbia | Anti-endotoxic, antimicrobial cationic peptides and methods of use therefor |
| WO2000026344A1 (en) * | 1998-10-30 | 2000-05-11 | Interlink Biotechnologies Llc | Peptides with enhanced stability to protease degradation |
| US6946261B1 (en) | 1998-11-20 | 2005-09-20 | Migenix Inc. | Efficient methods for producing anti-microbial cationic peptides in host cells |
| EP1185623A4 (en) * | 1999-03-03 | 2005-03-23 | Regents Board Of | Genetic and epigenetic manipulation of abc transporters and ecto-phosphatases for the conference of drug resistance and for the loss of drug resistance in biological systems and methods for the detection of ecto-phosphatase inhibitors |
| US6309633B1 (en) * | 1999-06-19 | 2001-10-30 | Nobex Corporation | Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same |
| US7169889B1 (en) | 1999-06-19 | 2007-01-30 | Biocon Limited | Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin |
| US6576224B1 (en) | 1999-07-06 | 2003-06-10 | Sinuspharma, Inc. | Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis |
| US6429211B1 (en) * | 2000-05-23 | 2002-08-06 | Bayer Corporation | Praziquantel compounds for treating diseases due to Sarcocystis Neospora Toxoplasma and Isospora |
| PL363153A1 (en) * | 2000-06-16 | 2004-11-15 | Hercules Incorporated | Chemically-modified antimicrobial peptides, compositions and methods of production and use |
| KR20090089922A (ko) | 2000-10-18 | 2009-08-24 | 파마셋 인코포레이티드 | 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한 변형된 뉴클레오시드 |
| US7214364B2 (en) | 2000-12-27 | 2007-05-08 | Corus Pharma, Inc. | Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections |
| DK2301524T3 (da) | 2000-12-27 | 2013-07-15 | Gilead Sciences Inc | Inhalerbar aztreonam uden arginin til behandling og forebyggelse af bakterielle lungeinfektioner |
| US6867183B2 (en) | 2001-02-15 | 2005-03-15 | Nobex Corporation | Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith |
| US7060675B2 (en) | 2001-02-15 | 2006-06-13 | Nobex Corporation | Methods of treating diabetes mellitus |
| US7115572B2 (en) * | 2001-03-29 | 2006-10-03 | Council Of Scientific And Industrial Research | Indolicidin analogs with anti-microbial activity |
| US6759058B1 (en) * | 2001-04-25 | 2004-07-06 | Western Center For Drug Development College Of Pharmacy Western University Of Health Sciences | Enteric-coated proliposomal formulations for poorly water soluble drugs |
| US8658202B2 (en) | 2001-04-25 | 2014-02-25 | Western University Of Health Sciences | Coated drug delivery formulations |
| US6858580B2 (en) | 2001-06-04 | 2005-02-22 | Nobex Corporation | Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| US6828297B2 (en) | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| US6713452B2 (en) | 2001-06-04 | 2004-03-30 | Nobex Corporation | Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| EP1401478A2 (en) * | 2001-06-22 | 2004-03-31 | The Hospital for Sick Children | Antimicrobial peptides |
| US6835536B2 (en) | 2001-08-21 | 2004-12-28 | Micrologix Biotech Inc. | Antimicrobial cationic peptides and formulations thereof |
| US6734165B2 (en) * | 2001-08-23 | 2004-05-11 | The Trustees Of Columbia University In The City Of New York | Method for re-sensitizing vancomycin resistant bacteria which selectively cleave a cell wall depsipeptide |
| US8933029B2 (en) * | 2001-08-24 | 2015-01-13 | Carrus Capital Corporation | Antimicrobial and anti-inflammatory peptides |
| US7166571B2 (en) | 2001-09-07 | 2007-01-23 | Biocon Limited | Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
| US7312192B2 (en) | 2001-09-07 | 2007-12-25 | Biocon Limited | Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
| US6913903B2 (en) | 2001-09-07 | 2005-07-05 | Nobex Corporation | Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
| US7196059B2 (en) | 2001-09-07 | 2007-03-27 | Biocon Limited | Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith |
| US20030219854A1 (en) * | 2002-03-21 | 2003-11-27 | Micrologix Biotech Inc. | Methods for producing modified anti-infective peptides |
| US7399583B2 (en) * | 2002-04-17 | 2008-07-15 | Novartis Ag | Method for the identification of inhibitors of the binding of ARE-containing mRNA and a HuR protein |
| AU2003231471A1 (en) * | 2002-04-25 | 2003-11-10 | Toagosei Co., Ltd. | Antimicrobial polypeptide and utizliation thereof |
| US7345018B2 (en) | 2002-04-25 | 2008-03-18 | Reception Aps | Method of treating side effects induced by therapeutic agents |
| WO2003105768A2 (en) | 2002-06-13 | 2003-12-24 | Nobex Corporation | Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus |
| IL150907A (en) * | 2002-07-25 | 2007-07-04 | Stephan Cherkez | Process for the preparation of stable amorphous calcium pseudomonate |
| SE0202613D0 (sv) | 2002-09-04 | 2002-09-04 | Innate Pharmaceuticals Ab | Förfarande och prob för identifiering av ämnen som modifierar bakteriers virulens, som sådana identifierade ämnen samt deras användning |
| US7238669B2 (en) * | 2002-09-11 | 2007-07-03 | The Curators Of The University Of Missouri | Phage-display peptides as novel antimicrobial agents against Haemophilus influenzae |
| US20050245582A1 (en) * | 2002-09-12 | 2005-11-03 | The Hartz Mountain Corporation | High concentration topical insecticides containing pyrethroids |
| WO2005014777A2 (en) * | 2002-10-16 | 2005-02-17 | Board Of Regents, The University Of Texas System | Methods and compositions for increasing the efficacy of biologically-active ingredients |
| KR20110079783A (ko) | 2003-02-19 | 2011-07-07 | 예일 유니버시티 | 항-바이러스 뉴클레오시드 유사체 및 바이러스 감염, 특히 에이치아이브이 감염의 치료방법 |
| US20040260454A1 (en) * | 2003-06-11 | 2004-12-23 | Basir Otman A. | Vibro-acoustic engine diagnostic system |
| US7189403B2 (en) * | 2003-06-30 | 2007-03-13 | Institut Pasteur | Attenuated flavivirus strains containing a mutated M-ectodomain and their applications |
| US20050171063A1 (en) * | 2003-10-20 | 2005-08-04 | Pawan Malhotra | Use of phosphono derivatives as anti-malarials |
| WO2005039557A1 (en) * | 2003-10-22 | 2005-05-06 | Council Of Scientific And Industrial Research | Use of selected amino acid-zinc complexes as anti-malarial |
| US7674771B2 (en) * | 2003-10-29 | 2010-03-09 | Toagosei Co., Ltd | Antimicrobial peptides and utilization of the same |
| CA2559208A1 (en) * | 2004-03-17 | 2005-09-29 | Mpex Pharmaceuticals, Inc. | Use and administration of bacterial efflux pump inhibitors |
| US7994225B2 (en) * | 2004-03-17 | 2011-08-09 | Rempex Pharmaceuticals, Inc. | Bacterial efflux pump inhibitors for the treatment of ophthalmic and otic infections |
| WO2005090385A2 (en) * | 2004-03-18 | 2005-09-29 | Ansata Therapeutics, Inc. | Compositions having antimicrobial activity and uses thereof |
| CN101027318B (zh) | 2004-07-19 | 2016-05-25 | 比奥孔有限公司 | 胰岛素-低聚物共轭物,制剂及其用途 |
| JP4507080B2 (ja) * | 2004-07-30 | 2010-07-21 | 東亞合成株式会社 | 抗菌ペプチド及びその利用 |
| US7588885B2 (en) * | 2004-08-06 | 2009-09-15 | Chung Yuan Christian University | Use of biocistronic DNA constructs for identifying compounds that inhibit IRES-dependent translation |
| US20060068020A1 (en) * | 2004-09-24 | 2006-03-30 | Cottrell Ian W | Encapsulated pharmaceutical agents |
| JP4730584B2 (ja) * | 2004-12-06 | 2011-07-20 | 東亞合成株式会社 | 抗菌ペプチド及びその利用 |
| EP1849474B1 (en) * | 2005-02-15 | 2016-09-07 | Toagosei Co., Ltd. | Antimicrobial peptide and use thereof |
| CA2617133C (en) | 2005-07-28 | 2014-09-30 | Biosynexus Incorporated | Compositions and methods for treating bacteria |
| US20090099062A1 (en) * | 2007-05-31 | 2009-04-16 | Ethan Lee | Pyrvinium For The Treatment of Cancer |
| US9241908B2 (en) | 2007-10-16 | 2016-01-26 | Biocon Limited | Orally administrable solid pharmaceutical composition and a process thereof |
| ES2559840T3 (es) * | 2008-06-04 | 2016-02-16 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos |
| JP2011195451A (ja) * | 2008-06-20 | 2011-10-06 | Fukuoka Univ | ペプチド |
| US8773662B2 (en) * | 2010-07-22 | 2014-07-08 | Vuv Analytics, Inc. | Methods and apparatus for vacuum ultraviolet (VUV) or shorter wavelength circular dichroism spectroscopy |
| WO2012017215A1 (en) * | 2010-08-05 | 2012-02-09 | Helperby Therapeutics Limited | Combination of a pyrroloquinoline compound and a beta-lactam antimicrobial agent, mupirocin or chlorhexidine |
| CN102167731B (zh) * | 2011-02-10 | 2013-01-23 | 周逸明 | 一种固相多肽合成奥米加南的制备方法 |
| WO2013056003A2 (en) | 2011-10-12 | 2013-04-18 | Yale University | Catechol diethers as potent anti-hiv agents |
| AU2014318837B2 (en) * | 2013-09-12 | 2019-05-30 | Janssen Biopharma, Inc. | Pyridazinone compounds and uses thereof |
| WO2015077057A1 (en) * | 2013-11-20 | 2015-05-28 | Texas Southern University | Methionine aminopeptidase inhibitors for treating infectious diseases |
| RU2678985C2 (ru) * | 2017-02-06 | 2019-02-05 | Общество с ограниченной ответственностью "Научно-производственная фирма ВЕРТА" | Биоцидный пептид и препарат на его основе |
| CN108721292B (zh) * | 2018-05-04 | 2022-04-01 | 中国疾病预防控制中心病毒病预防控制所 | 扑蛲灵在制备广谱抗冠状病毒药物中的应用 |
| US12702790B2 (en) | 2019-06-13 | 2026-08-11 | Hollister Incorporated | Reusable urinary catheter kits |
| LT3952973T (lt) | 2019-06-13 | 2023-07-10 | Hollister Incorporated | Daugkartinio naudojimo šlapimo kateterio produktai |
| WO2020263859A1 (en) | 2019-06-25 | 2020-12-30 | Hollister Incorporated | Reusable urinary catheter products |
| KR102433665B1 (ko) * | 2021-11-17 | 2022-08-19 | 주식회사 씨위드 | 인돌리시딘 유래 항균 펩타이드 및 이의 용도 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2128617A (en) | 1982-10-06 | 1984-05-02 | Martti Vaara | Polypeptides for use in antibacterial therapy |
| NZ237202A (en) | 1990-02-23 | 1994-01-26 | Bristol Myers Squibb Co | Composition containing beta-lactam antibiotic and cationic oligopeptide |
| US5547939A (en) | 1991-06-14 | 1996-08-20 | The Regents Of The University Of California | Broad spectrum antimicrobial compounds and methods of use |
| US5324716A (en) | 1991-06-14 | 1994-06-28 | Regents Of The University Of California | Broad spectrum antimicrobial compounds and methods of use |
| US5593866A (en) | 1992-08-21 | 1997-01-14 | The University Of British Columbia | Cationic peptides and method for production |
| US5359030A (en) | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
| US5681811A (en) | 1993-05-10 | 1997-10-28 | Protein Delivery, Inc. | Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same |
| DK0759774T3 (da) | 1993-09-22 | 2002-10-07 | Xoma Technology Ltd | Fremgangsmåde til behandling af gram-negativ bakteriel infektion ved indgivelse af baktericidt/permeabilitet-forøgende (BPI) proteinprodukt og antibiotikum |
| DE69424680T2 (de) * | 1993-10-25 | 2000-09-28 | The Liposome Co.,Inc. | Liposomale defensine |
| CA2181164C (en) | 1994-01-14 | 2008-01-08 | Arnold Horwitz | Anti-gram-positive bacterial methods and materials |
| US5574017A (en) * | 1994-07-05 | 1996-11-12 | Gutheil; William G. | Antibacterial agents |
| US5877274A (en) | 1995-06-02 | 1999-03-02 | University Of British Columbia | Antimicrobial cationic peptides |
| DE69637731D1 (de) | 1995-08-23 | 2008-12-11 | Univ British Columbia | Antimikrobielle kationische peptide und methoden zu ihrer identifizierung |
| US5994308A (en) | 1996-02-28 | 1999-11-30 | Board Of Trustees Of Southern Illinois University | Broad spectrum antimicrobial peptides containing a tryptophan triplet and methods of use |
| US6503881B2 (en) * | 1996-08-21 | 2003-01-07 | Micrologix Biotech Inc. | Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics |
| US6180604B1 (en) * | 1996-08-21 | 2001-01-30 | Micrologix Biotech Inc. | Compositions and methods for treating infections using analogues of indolicidin |
| US6551994B1 (en) | 1997-04-10 | 2003-04-22 | Mcgill University | Compounds and methods for inhibiting the interaction between α-catenin and β-catenin |
| WO1999043357A1 (en) | 1998-02-25 | 1999-09-02 | Micrologix Biotech Inc. | Indolicidin and cationic peptides conjugated with polymers |
-
1997
- 1997-08-20 US US08/915,314 patent/US6180604B1/en not_active Expired - Lifetime
- 1997-08-21 WO PCT/US1997/014779 patent/WO1998007745A2/en not_active Ceased
- 1997-08-21 CA CA002263799A patent/CA2263799A1/en not_active Abandoned
- 1997-08-21 ES ES01119148T patent/ES2315252T3/es not_active Expired - Lifetime
- 1997-08-21 DE DE69739035T patent/DE69739035D1/de not_active Expired - Lifetime
- 1997-08-21 AT AT01119148T patent/ATE410441T1/de not_active IP Right Cessation
- 1997-08-21 AT AT97941352T patent/ATE218579T1/de active
- 1997-08-21 DE DE69713112T patent/DE69713112T2/de not_active Expired - Lifetime
- 1997-08-21 EP EP97941352A patent/EP0925308B1/en not_active Expired - Lifetime
- 1997-08-21 ES ES97941352T patent/ES2178000T3/es not_active Expired - Lifetime
- 1997-08-21 JP JP10510994A patent/JP2001500477A/ja active Pending
-
2000
- 2000-09-22 US US09/667,486 patent/US6538106B1/en not_active Expired - Fee Related
-
2002
- 2002-07-08 HK HK02105059.5A patent/HK1043475B/en not_active IP Right Cessation
-
2003
- 2003-01-24 US US10/351,985 patent/US7390787B2/en not_active Expired - Fee Related
-
2004
- 2004-08-23 JP JP2004242925A patent/JP4073900B2/ja not_active Expired - Fee Related
-
2008
- 2008-03-28 US US12/058,500 patent/US20080242614A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20040009910A1 (en) | 2004-01-15 |
| EP0925308B1 (en) | 2002-06-05 |
| ATE410441T1 (de) | 2008-10-15 |
| JP2005225857A (ja) | 2005-08-25 |
| US6180604B1 (en) | 2001-01-30 |
| WO1998007745A2 (en) | 1998-02-26 |
| US20080242614A1 (en) | 2008-10-02 |
| DE69713112T2 (de) | 2003-01-30 |
| WO1998007745A3 (en) | 1998-07-09 |
| US7390787B2 (en) | 2008-06-24 |
| EP0925308A2 (en) | 1999-06-30 |
| DE69713112D1 (de) | 2002-07-11 |
| HK1043475A1 (en) | 2002-09-13 |
| US6538106B1 (en) | 2003-03-25 |
| CA2263799A1 (en) | 1998-02-26 |
| HK1021824A1 (en) | 2000-07-07 |
| ES2315252T3 (es) | 2009-04-01 |
| HK1043475B (en) | 2009-07-03 |
| JP2001500477A (ja) | 2001-01-16 |
| ATE218579T1 (de) | 2002-06-15 |
| JP4073900B2 (ja) | 2008-04-09 |
| DE69739035D1 (de) | 2008-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69713112D1 (de) | Zusammensetzungen und methoden zur behandlung von infektionen unter verwendung von indolicidin-analogen | |
| ATE333464T1 (de) | Zusammensetzungen und verfahren zur behandlung von infektionen unter verwendung von kationischen peptiden allein oder in kombination mit antibiotika | |
| DE69731373D1 (de) | Cc-chemokinzeptor c-c ckr-5, dessen derivate und verwendungen | |
| AU6020099A (en) | Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein | |
| MX9703643A (es) | Metodos para tratamiento de esclerosis multiple usando analogos de peptidos de proteina basica de mielina humana. | |
| EP0720482A4 (en) | PROSAPOSIN AND CYTOKIN-DERIVED PEPTIDES AS THERAPEUTIC ACTIVE SUBSTANCES | |
| BR9708911A (pt) | Composto fragmento de peptídeo processo par tratar uma doença em um paciente em necessidade de terapia antioangiogênese composição polinucleotídeo único ou de duplo-filamento isolado vetor e processo para produzir um fragmento de peptídeo de kringle 5 ou proteína de fusão de kringle 5 solúvel | |
| MX9705954A (es) | Formulaciones y metodos para reducir irritacion de la piel. | |
| ATE270557T1 (de) | Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen | |
| BR9907995A (pt) | Métodos imunológicos para modular miostatina em sujeitos vertebrados | |
| WO2002048183A3 (en) | Compositions of peptide crystals | |
| NO971889L (no) | Forbindelser og sammensetninger for levering av aktive midler | |
| AR016751A1 (es) | Metodo para inhibir la liberacion del peptido beta-amiloide en una celula, composicion farmaceutica y compuestos utiles en dicho metodo | |
| DK0728148T3 (da) | Forbedrede immunogene sammensætninger mod humant gastrin 17 | |
| UA65561A (en) | Therapeutic agent for lymphatic tumors | |
| HUT62916A (en) | Process for producing immunogenic peptides and pharmaceutical compositions comprising same | |
| WO1996028470A3 (en) | Peptide analogues of human myelin basic protein useful in treating multiple sclerosis | |
| ES2180948T3 (es) | Peptido que proviene de una forma soluble de la acetilcolinesterasa, activo como modulador del canal. | |
| DK525384D0 (da) | Praeparat paa basis af faktor viii til behandling af haemofili a inhibitorpatienter samt fremgangsmaade til fremstilling af et saadan praeparat | |
| BG103872A (en) | Glycoconjugates of 20(s)-camptotecin | |
| WO2002058589A3 (en) | Agents and methods for promoting bone growth | |
| EP1174439A3 (en) | Compositions and methods for treating infections using analogues of indolicidin | |
| EA200100395A1 (ru) | Фармацевтическая композиция, содержащая фрагменты днк, кодирующей антигенный белок, обладающая противоопухолевым действием | |
| AU8811298A (en) | Novel peptides and polypeptides useful for regenerating the nervous system | |
| PT938329E (pt) | Composicao de tlp imunogenica |